
FDA Approves Updated Labels on 2 CAR T-Cell Therapies
The FDA has approved label updates for lisocabtagene maraleucel (liso-cel; Breyanzi) and idecabtagene vicleucel (ide-cel; Abecma), significantly reducing patient monitoring requirements and eliminating their respective Risk Evaluation and Mitigation …